Mirador Therapeutics envisions a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and better development accuracy.
Driven by our deep
expertise and passion.
Founded and led by several former executives of Prometheus Biosciences (acquired in 2023 by Merck for $10.8 billion). From the architects of the precision medicine revolution, we are approaching I&I with a proven track record and from a unique “mirador” or “vantage point” of knowledge and experience.
To accelerate the development of precision medicines in I&I, our Mirador360™ precision development engine incorporates the latest advances in human genetics and data science.